PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Cheng, Haiying, Zhang, Zhenfeng, Borczuk, Alain, Powell, Charles A., Balajee, Adayabalam S., Lieberman, Howard B., Halmos, Balazs
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2013
Pynciau:
Original Manuscript
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616665/
https://ncbi.nlm.nih.gov/pubmed/23275151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgs393
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg